RT Journal Article
SR Electronic
A1 Lederman, Lynne
T1 TP53 Mutations Are Associated With Increased Pathologic Complete Response in HER2-Positive BC
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 56
SP 8
OP 9
DO 10.1177/1559897715571070
UL http://mdc.sagepub.com/content/14/56/8.abstract
AB Patients with stage II or stage III breast cancer treatable by surgery received neoadjuvant therapy with paclitaxel and trastuzumab with or without lapatinib. A mutational analysis on pretreatment tumors showed frequent mutations in TP53; these were associated with a greater rate of pathologic complete remission.